Aarti Pharmalabs growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−14.0%+14.2%−4.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−20.5%+20.3%+12.9%
−29.8%+20.7%+11.9%
−35.9%+25.6%+12.1%
−35.9%+25.6%+12.1%
+19.8%+12.6%+15.7%
+6.8%+13.3%+12.7%
−21.0%+53.2%−17.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIPHARM₹927.65

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹8,410 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-4.8+14.2-14.0—
EBITDA Growth—+12.9+20.3-20.5—
EBIT Growth—+11.9+20.7-29.8—
Net Income Growth—+12.1+25.6-35.9—
EPS Growth—+12.1+25.6-35.9—
Total Assets Growth—+15.7+12.6+19.8—
Total Equity Growth—+12.7+13.3+6.8—
Cash from Operations Growth—-17.7+53.2-21.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.